Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024, and January 23, 2026, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against BlackRock TCP - The complaint alleges that during the class period, BlackRock TCP failed to disclose that its investments were not being timely or appropriately valued [2]. - It is claimed that the company's portfolio restructuring efforts were ineffective in resolving challenged credits or improving portfolio quality [2]. - The lawsuit asserts that the company's unrealized losses were understated, leading to an overstatement of the company's net asset value (NAV) [2]. - As a result of these issues, the positive statements made by the defendants about the company's business and prospects were materially misleading [2]. Group 2: Financial Disclosure and Impact - On January 23, 2026, BlackRock TCP disclosed that its NAV per share as of December 31, 2025, was between $7.05 and $7.09, which is 19% lower than the previous quarter and 23.4% lower than the previous year [3]. - Following this disclosure, BlackRock TCP's stock price dropped by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026 [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by April 6, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show statistically significant improvement on its primary endpoint, leading to a dramatic stock price drop from $4.36 to $0.86, a decline of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [4].

Group 1 - The Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Plug Power Inc. for the period between January 17, 2025, and November 13, 2025 [1] - The lawsuit alleges that Plug Power misled investors regarding its business operations, specifically concerning the availability of funds from the U.S. Department of Energy and the construction of hydrogen production facilities [2][3] - The lawsuit claims that Plug Power overstated the likelihood of receiving government funds and indicated a potential pivot to less ambitious projects, leading to materially false and misleading public statements [3] Group 2 - Shareholders interested in serving as lead plaintiffs must file motions with the court by April 3, 2026, and can remain absent class members if they choose not to participate [4] - Rosen Law Firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5] - The firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6]

Core Viewpoint - A class action has been filed against Ramaco Resources, Inc. for allegedly overstating development progress at its Brook Mine, with claims that no significant mining activity has occurred since its groundbreaking in July 2025 [1][2]. Group 1: Allegations and Investigations - Robbins LLP is investigating allegations that Ramaco Resources, Inc. failed to disclose the lack of significant mining activity at the Brook Mine after its groundbreaking [2]. - A report by Wolfpack Research claims that the Brook Mine is a "hoax" and that no active mining has taken place, supported by drone footage showing no work occurring three months post-groundbreaking [3]. Group 2: Stock Impact - Following the publication of the Wolfpack Research report, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025 [3]. Group 3: Class Action Participation - Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by March 31, 2026, although participation is not required to be eligible for recovery [4].

Core Viewpoint - A class action has been filed against SLM Corporation (Sallie Mae) for allegedly misleading investors about its loss mitigation and loan modification programs during a specific period in 2025 [1][2]. Group 1: Allegations and Findings - The complaint alleges that SLM failed to disclose a significant increase in early stage delinquencies, leading to an overstatement of the effectiveness of its loss mitigation and loan modification programs [2]. - A report from TD Cowen indicated that July 2025 delinquencies rose by 49 basis points month-over-month, which was worse than the expected seasonal increase of 10 basis points, driven by a 45 basis point increase in early stage delinquencies [3]. - The findings from TD Cowen contradicted SLM's previous assurances regarding delinquency rates following normal seasonal trends, resulting in a stock price drop of $2.67 per share (8.09%) to close at $30.32 on August 15, 2025 [3]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against SLM Corporation, with the option to serve as lead plaintiff or remain an absent class member [4]. - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action has been filed against F5, Inc. for allegedly misleading investors regarding the financial impact of a significant security breach that occurred between October 28, 2024, and October 27, 2025 [1][3]. Group 1: Class Action Details - The class period for the action is defined as October 28, 2024, to October 27, 2025 [3]. - Robbins LLP is investigating allegations that F5, Inc. misled investors about its ability to secure client data amid a significant security breach [3]. - The breach reportedly compromised the company's BIG-IP product development and engineering knowledge management platforms, including the source code [4]. Group 2: Financial Impact - Following the announcement of the security breach on October 15, 2025, F5's stock price fell from $343.17 per share on October 14, 2025, to $295.35 per share on October 16, 2025, marking a decline of approximately 13.9% [4]. - On October 27, 2025, F5 reported fourth-quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, attributing this to the security breach [5]. - The company indicated expected reductions in sales and renewals, elongated sales cycles, and increased expenses due to ongoing remediation efforts, which further impacted its stock price, dropping from $290.41 per share on October 27, 2025, to $258.76 per share on October 28, 2025, a decline of an additional 10.9% [5]. Group 3: Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by February 17, 2026, to serve as lead plaintiff [6]. - Shareholders can choose to remain absent class members without participating in the case [6].

Core Viewpoint - A class action has been filed against Bath & Body Works, Inc. for allegedly misleading investors regarding its business strategy and financial performance [1][2]. Allegations - The complaint alleges that Bath & Body Works did not disclose that its strategy of pursuing "adjacencies, collaborations and promotions" was failing to grow the customer base and was not delivering the expected growth in net sales [2]. - It is claimed that the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [2]. Financial Performance - On November 20, 2025, Bath & Body Works reported disappointing third quarter results, with revenue declining by 1% year over year, missing the guidance of 1-3% growth, and a net income drop of 26% to $77 million [3]. - The company revised its full-year guidance for net sales and reduced expected earnings per diluted share from $3.28 to "at least $2.83" [3]. - In an investor presentation, the company acknowledged that its strategy had not grown the total customer base and identified issues such as reduced focus on core categories and over-reliance on promotions [3]. Stock Market Reaction - Following the announcement of poor financial results and strategic changes, Bath & Body Works' stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [4]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by March 16, 2026, to serve as lead plaintiff, representing other class members [4].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misleading investors regarding its accounts receivable and financial reporting [1][2]. Group 1: Allegations - The complaint states that Ardent Health reported inflated accounts receivable and delayed recognizing losses on uncollectable accounts [2]. - It is alleged that Ardent Health did not maintain sufficient professional malpractice liability insurance to cover claims arising from its operations [2]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, leading to a significant stock price drop of nearly 34% [2]. Group 2: Legal Actions - Shareholders who purchased Ardent Health securities between July 18, 2025, and November 12, 2025, may be eligible to participate in the class action [1][3]. - Interested shareholders must submit their papers to the court by March 9, 2026, to serve as lead plaintiff [3]. Group 3: Company Background - Ardent Health, Inc. operates acute care hospitals and other healthcare facilities [1].

Rosen Law Firm Urges Ramaco Resources, Inc. (NASDAQ: METC) Stockholders to Contact the Firm for Information About Their RightsFeb 2, 2026 12:30 PM Eastern Standard Time# Rosen Law Firm Urges Ramaco Resources, Inc. (NASDAQ: METC) Stockholders to Contact the Firm for Information About Their RightsShare---NEW YORK--([BUSINESS WIRE])--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Ramaco Resources, Inc. (NASDAQ: METC) between July 31, ...

Core Viewpoint - A class action has been filed against Bitdeer Technologies Group, alleging that the company misled investors about its business prospects and the development of its SEALMINER A4 machine [1][2]. Group 1: Allegations and Misleading Information - The complaint claims that Bitdeer created a false impression regarding its reliable information on the development of the SEALMINER A4 machine, which was expected to enhance revenue through self-mining and external sales in fiscal year 2025 [2]. - Defendants allegedly misrepresented the progress of the SEAL04 chip design, which faced issues leading to delays in production and a "dual-track approach" to ensure mass production [2]. Group 2: Financial Performance and Market Reaction - On November 10, 2025, Bitdeer reported a net loss of $266.7 million, or $1.28 per share, primarily due to increased operating expenses related to R&D of its ASICs roadmap [3]. - Following the financial results announcement, Bitdeer's stock price dropped over 14%, from $17.65 per share to $15.02 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must file their papers by February 2, 2026, to serve as lead plaintiff, representing other class members [4]. - Shareholders can remain absent class members without participating in the case and still be eligible for recovery [4]. Group 4: Company Background - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].